Physician profile
Roy E Gondo
NPI 1669476131
$10,419.65
in general payments reported to CMS, 2019-2025
40 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $662 · 2021: $1,443 · 2022: $1,948 · 2023: $1,802 · 2024: $1,929 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,570 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,570.00 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,001.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,143.84 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,047.73 | 2019-2025 | Jardiance |
| Pfizer INC. | $808.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $733.87 | 2021-2025 | |
| Novo Nordisk INC | $603.03 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $559.33 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $535.75 | 2019-2023 | Shingrix, Bexsero, Pediarix |
| Janssen Pharmaceuticals, INC | $348.24 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $285.21 | 2024-2025 | Voquezna |
| Amgen INC. | $253.82 | 2019-2024 | Evenity, Prolia, Otezla |
| Sumitomo Pharma America, INC. | $226.18 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $207.51 | 2019-2024 | Veozah |
| Mylan Specialty L.P. | $161.57 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $133.54 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $124.99 | 2025 | |
| Lilly USA, LLC | $119.27 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $107.72 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $107.32 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $103.29 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boston Scientific Corporation | $98.25 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $84.85 | 2021-2023 | Eliquis |
| Insmed, INC. | $70.22 | 2025 | Arikayce, Brinsupri |
| Kowa Pharmaceuticals America, INC. | $58.56 | 2023-2024 | Livalo, Zoryve, Seglentis |
| Esperion Therapeutics, INC. | $55.80 | 2021-2025 | Nexletol |
| Viatris Specialty LLC | $55.80 | 2025 | Yupelri |
| Harmony Biosciences LLC | $50.48 | 2021-2023 | Wakix |
| Daiichi Sankyo INC. | $48.27 | 2022-2025 | Injectafer |
| Xeris Pharmaceuticals, INC. | $46.29 | 2024 | Gvoke Hypopen |
| Allergan, INC. | $43.67 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.97 | 2021-2025 | Xifaxan |
| Biogen, INC. | $27.65 | 2024 | Leqembi |
| Otsuka America Pharmaceutical, INC. | $19.57 | 2019 | |
| Dexcom, INC. | $18.69 | 2023 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $18.42 | 2020 | |
| Hologic Sales and Service, LLC | $17.95 | 2023 | Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $15.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.36 | 2022 | |
| Bardy Diagnostics, INC. | $13.05 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Gondo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.